Stocks / Stock overview

ImmunityBio, Inc. (IBRX)

$7.79-0.64%Aft $7.78 (-0.13%)Market cap $8.26B

NasdaqGS · Price as of · Nasdaq Real Time Price

Stock Scorer
Scoring…
Analyst consensus
Rated$12.75
  • Analysts4
  • Implied upside+63.7%
  • Target range$12.00 to $15.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
November 3, 2026date estimated
  • EPS expected-$0.05
  • A year ago-$0.07
  • Revenue expected$59.2M +85%
  • Estimate range-$0.09 to $0.00
Consensus of 3 analysts for the quarter ending September 30, 2026. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
SCHEDULE 13D/AAugust 6, 2026View on EDGAR
10-QAugust 4, 202610-Q
8-KAugust 4, 20268-K
8-KJuly 30, 20268-K
4July 6, 2026FORM 4
4July 6, 2026FORM 4
144July 2, 2026View on EDGAR
4July 1, 2026FORM 4
All SEC filings

Frequently asked questions

When does IBRX report earnings?

ImmunityBio, Inc. (IBRX) is scheduled to report quarterly results on November 3, 2026 (estimated). The 3-analyst consensus is -$0.05 per share on revenue of $59.2M for the quarter ending September 30, 2026, against -$0.07 and $32.1M a year earlier. The date is an estimate from past reporting patterns and can move until the company confirms it.

What do analysts expect for IBRX?

4 analysts cover ImmunityBio, Inc. (IBRX). No consensus rating has been published. The average price target is $12.75, in a range of $12.00 to $15.00.

Are insiders buying or selling IBRX?

We have no qualifying Form 4 insider purchases or sales on record for ImmunityBio, Inc. (IBRX). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see IBRX SEC filings?

Recent filings are listed on this page, newest first. The latest is a SCHEDULE 13D/A filed August 6, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.